Aspergillosis Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com

News provided by

RnR Market Research

Jul 21, 2015, 06:30 ET

Dallas, TX (PRWEB) July 21, 2015 -- The report “Aspergillosis - Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Aspergillosis. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. Complete report on Aspergillosis with 35 market data tables and 16 figures, spread across 98 pages is available at http://www.rnrmarketresearch.com/aspergillosis-pipeline-review-h1-2015-market-report.html .

Companies discussed in this report includes Amplyx Pharmaceuticals, Inc., Astellas Pharma Inc., Aureogen Biosciences, Inc., Basilea Pharmaceutica AG, Biomar Microbial Technologies, Eisai Co., Ltd., F2G Ltd, iCo Therapeutics Inc., MABLife S.A.S, Merck & Co., Inc., Nanomerics Ltd, Novabiotics Ltd, Pulmocide Ltd, Scynexis, Inc., Sealife PHARMA GMBH, Sigma-Tau S.p.A., Vical Incorporated.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are amphotericin b, amphotericin B, amphotericin b NanoDisk, ASP-2397, ASP-9726, AUGC-10, AUGC-15, C-001, C-016, E-1210, E-1211, F-901318, FK506 Analogues, GBV-042, isavuconazonium sulfate, KB-425796C, MAT-401, MDN-0018, NP-339, posaconazole, PTX-3, SCY-078, SLP-0901, SLP-0904, Small Molecules for Aspergillosis and Candidiasis, Small Molecules for Fungal Infections, Small Molecules for Fungal Infections, Small Molecules for Invasive Pulmonary Aspergillosis, Small Molecules to Inhibit ABC Transporter for Fungal Infections.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=395211 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report are:
• Apr 27, 2015: Astellas Launches CRESEMBA (isavuconazonium sulfate) in the United States for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis
• Apr 23, 2015: CRESEMBA (isavuconazonium sulfate) Data to be Presented at the European Congress of Clinical Microbiology and Infectious Diseases
• Mar 25, 2015: Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas
• Mar 06, 2015: FDA approves new antifungal drug Cresemba
• Jan 22, 2015: Astellas Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval of CRESEMBA (isavuconazonium) for Treatment of Invasive Aspergillosis and Mucormycosis
• Jan 09, 2015: SCYNEXIS Receives FDA Fast Track Designation for Oral Formulation of SCY-078 for the Treatment of Patients With Invasive Fungal Infections
• Nov 21, 2014: Basilea Reports That U.S. FDA Sets Date Of Advisory Committee Meeting On Isavuconazole NDA For The Treatment Of Invasive Aspergillosis And Mucormycosis
• Sep 09, 2014: F2G Announces A Major Funding Award From The Technology Strategy Board`s Biomedical Catalyst
• Sep 06, 2014: Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis
• Sep 05, 2014: Astellas to Showcase Isavuconazole Data at ICAAC

Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=395211 . (This is a premium report priced at US$2000 for a single user License.)

List of Tables

Number of Products under Development for Aspergillosis, H1 2015
Number of Products under Development for Aspergillosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Aspergillosis - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2015
Aspergillosis - Pipeline by Astellas Pharma Inc., H1 2015
Aspergillosis - Pipeline by Aureogen Biosciences, Inc., H1 2015
Aspergillosis - Pipeline by Basilea Pharmaceutica AG, H1 2015
Aspergillosis - Pipeline by Biomar Microbial Technologies, H1 2015
Aspergillosis - Pipeline by Eisai Co., Ltd., H1 2015
Aspergillosis - Pipeline by F2G Ltd, H1 2015
Aspergillosis - Pipeline by iCo Therapeutics Inc., H1 2015
Aspergillosis - Pipeline by MABLife S.A.S, H1 2015
Aspergillosis - Pipeline by Merck & Co., Inc., H1 2015
Aspergillosis - Pipeline by Nanomerics Ltd, H1 2015
Aspergillosis - Pipeline by Novabiotics Ltd, H1 2015
Aspergillosis - Pipeline by Pulmocide Ltd, H1 2015
Aspergillosis - Pipeline by Scynexis, Inc., H1 2015
Aspergillosis - Pipeline by Sealife PHARMA GMBH, H1 2015
Aspergillosis - Pipeline by Sigma-Tau S.p.A., H1 2015
Aspergillosis - Pipeline by Vical Incorporated, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015

Explore more reports on Infectious Diseases Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]